Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 20/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 20/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299401 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1B | |
| SCHEMBL4689360 | 0.82 | MTNR1A (0.80) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL2296995 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL2299672 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL29426436 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL2296992 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL2298060 | 0.81 | MTNR1A (0.76) | MTNR1AMTNR1B | |
| SCHEMBL2297247 | 0.80 | MTNR1A (0.78) | MTNR1AMTNR1B | |
| SCHEMBL2296546 | 0.79 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL2300417 | 0.79 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400940-B1 | COMPOUNDS HAVING MELATONIN RECEPTOR AFFINITY AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICALS CO (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-108697689-B | Prophylactic or therapeutic agent for autism spectrum disorder | 武田药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-20220096444-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-31 | — | — | US | disclosed |
| EP-3400939-B1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-11173147-B2 | Prophylactic or therapeutic agent for delirium | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-11173147-B2 | Prophylactic or therapeutic agent for delirium | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210130305-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20210130305-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2021-05-06 | — | — | US | disclosed |
| US-10759768-B2 | Prophylactic or therapeutic agent for autism spectrum disorder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-01 | — | — | US | disclosed |
| US-10759768-B2 | Prophylactic or therapeutic agent for autism spectrum disorder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20110196003-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-11 | — | — | US | disclosed |
| US-20110190361-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190361-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190361-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-2029561-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007148808-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007148808-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190361-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, CYP11B2 | MTNR1A 1/4885MTNR1B 2/4885NQO2 1121/4885 |
| US-20110196003-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, CYP11B2 | MTNR1A 1/4885MTNR1B 2/4885NQO2 1121/4885 |
| US-20220096444-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | MTNR1A, MTNR1B, PNMT | MTNR1A 1/4885MTNR1B 2/4885NQO2 812/4885 |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, CYP11B2 | MTNR1A 1/4885MTNR1B 2/4885NQO2 1121/4885 |
| US-11173147-B2 | Prophylactic or therapeutic agent for delirium | MTNR1A, MTNR1B, PNMT | MTNR1A 1/4885MTNR1B 2/4885NQO2 812/4885 |
| US-20210130305-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885NQO2 2386/4885 |
| US-10759768-B2 | Prophylactic or therapeutic agent for autism spectrum disorder | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885NQO2 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.